Different Expression Patterns of VISTA Concurrent With PD-1, Tim-3, and TIGIT on T Cell Subsets in Peripheral Blood and Bone Marrow from Patients With Multiple Myeloma

Cross Center Single-Cell Rna Sequencing Study of The Immune Microenvironment in Rapid Progressing Multiple Myeloma

Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX)

Teclistamab in the Treatment of Relapsed or Refractory Multiple Myeloma

Immune Dysfunctions Affecting Bone Marrow Vγ9Vδ2 T Cells in Multiple Myeloma: Role of Immune Checkpoints and Disease Status

Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma

Early Cytopenias and Infections After Standard of Care Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma

Different Expression Patterns of VISTA Concurrent With PD-1, Tim-3, and TIGIT on T Cell Subsets in Peripheral Blood and Bone Marrow from Patients With Multiple Myeloma

header-info

Nov, 23, 2022

VISTA was found to be closely associated with disease progression and clinical indicators, suggesting that VISTA may be considered a potential target for reversing T cell exhaustion and improving T cell function in MM.